Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

265 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Molecular and clinical features of the myeloproliferative neoplasm associated with JAK2 exon 12 mutations.
Passamonti F, Elena C, Schnittger S, Skoda RC, Green AR, Girodon F, Kiladjian JJ, McMullin MF, Ruggeri M, Besses C, Vannucchi AM, Lippert E, Gisslinger H, Rumi E, Lehmann T, Ortmann CA, Pietra D, Pascutto C, Haferlach T, Cazzola M. Passamonti F, et al. Among authors: gisslinger h. Blood. 2011 Mar 10;117(10):2813-6. doi: 10.1182/blood-2010-11-316810. Epub 2011 Jan 11. Blood. 2011. PMID: 21224469 Free article.
Clonal analysis of deletions on chromosome 20q and JAK2-V617F in MPD suggests that del20q acts independently and is not one of the predisposing mutations for JAK2-V617F.
Schaub FX, Jäger R, Looser R, Hao-Shen H, Hermouet S, Girodon F, Tichelli A, Gisslinger H, Kralovics R, Skoda RC. Schaub FX, et al. Among authors: gisslinger h. Blood. 2009 Feb 26;113(9):2022-7. doi: 10.1182/blood-2008-07-167056. Epub 2008 Dec 1. Blood. 2009. PMID: 19047681 Free article.
The 'GGCC' haplotype of JAK2 confers susceptibility to JAK2 exon 12 mutation-positive polycythemia vera.
Olcaydu D, Skoda RC, Looser R, Li S, Cazzola M, Pietra D, Passamonti F, Lippert E, Carillo S, Girodon F, Vannucchi A, Reading NS, Prchal JT, Ay C, Pabinger I, Gisslinger H, Kralovics R. Olcaydu D, et al. Among authors: gisslinger h. Leukemia. 2009 Oct;23(10):1924-6. doi: 10.1038/leu.2009.110. Epub 2009 May 14. Leukemia. 2009. PMID: 19440215 No abstract available.
Deletions of the transcription factor Ikaros in myeloproliferative neoplasms.
Jäger R, Gisslinger H, Passamonti F, Rumi E, Berg T, Gisslinger B, Pietra D, Harutyunyan A, Klampfl T, Olcaydu D, Cazzola M, Kralovics R. Jäger R, et al. Among authors: gisslinger h, gisslinger b. Leukemia. 2010 Jul;24(7):1290-8. doi: 10.1038/leu.2010.99. Epub 2010 May 27. Leukemia. 2010. PMID: 20508609
Incidence and risk factors for bleeding in 1104 patients with essential thrombocythemia or prefibrotic myelofibrosis diagnosed according to the 2008 WHO criteria.
Finazzi G, Carobbio A, Thiele J, Passamonti F, Rumi E, Ruggeri M, Rodeghiero F, Randi ML, Bertozzi I, Vannucchi AM, Antonioli E, Gisslinger H, Buxhofer-Ausch V, Gangat N, Rambaldi A, Tefferi A, Barbui T. Finazzi G, et al. Among authors: gisslinger h. Leukemia. 2012 Apr;26(4):716-9. doi: 10.1038/leu.2011.258. Epub 2011 Sep 16. Leukemia. 2012. PMID: 21926959
Mutations with epigenetic effects in myeloproliferative neoplasms and recent progress in treatment: Proceedings from the 5th International Post-ASH Symposium.
Tefferi A, Abdel-Wahab O, Cervantes F, Crispino JD, Finazzi G, Girodon F, Gisslinger H, Gotlib J, Kiladjian JJ, Levine RL, Licht JD, Mullally A, Odenike O, Pardanani A, Silver RT, Solary E, Mughal T. Tefferi A, et al. Among authors: gisslinger h. Blood Cancer J. 2011 Mar 4;1(3):e7. doi: 10.1038/bcj.2011.4. Blood Cancer J. 2011. PMID: 23471017 Free PMC article.
265 results